title: Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma.
abstract: Survivin is a member of the inhibitors of apoptosis and frequently overexpressed in various cancer cells. Overexpression of survivin in lung cancer cells attenuates antitumor effect of tyrosine kinase inhibitors. However, data from the previous studies on the clinicopathologic implication of survivin in non-small-cell lung carcinoma (NSCLC) are inconsistent. We investigated the expression of survivin in 373 cases of surgically resected NSCLC. Correlations between the expression of survivin and clinicopathologic, molecular features and prognostic significance were analyzed. In adenocarcinoma, the increased expression of survivin was associated with the presence of vascular invasion, lymph node metastasis, and tumor recurrences, but we didn't find any correlation with survivin expression and clinicopathological parameters in squamous cell carcinoma. Patients with high survivin expression had significantly shorter disease-free survival (DFS; 42.2 vs. 58.8 months; p = 0.001) and shorter overall survival (OS; 60.8 vs. 71.5 months; p = 0.009) than those with low survivin expression group in adenocarcinoma. In squamous cell carcinoma, the expression of survivin was not associated with prognosis of the patients (DFS; 48.9 vs. 48.7 months; p = 0.837, OS; 61.0 vs. 62.4 months; p = 0.771). Multivariate analysis confirmed that survivin was an independent poor prognostic factor in adenocarcinoma (DFS: hazard ratio (HR), 1.687; 95 % confidence interval (CI), 1.123-2.532; p = 0.012; OS: HR, 1.965; 95 % CI, 1.108-3.486; p = 0.021). There was no statistically significant difference in the expression of survivin among different molecular subgroups (p > 0.05). Our results suggest that survivin is an independent negative prognostic factor in adenocarcinoma, but not in squamous cell carcinoma. The different prognostic roles played by survivin in adenocarcinoma and squamous cell carcinoma highlights the biological differences between these two histologic types.
authors.affiliation: Department of Pathology, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam, Gyeonggi-do 463-707, Republic of Korea.
authors.forename: Ping-Li
authors.initials: PL
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: Jin
authors.forename: Hyojin
authors.initials: H
authors.lastname: Kim
authors.forename: An Na
authors.initials: AN
authors.lastname: Seo
authors.forename: Sanghoon
authors.initials: S
authors.lastname: Jheon
authors.forename: Choon-Taek
authors.initials: CT
authors.lastname: Lee
authors.forename: Jin-Haeng
authors.initials: JH
authors.lastname: Chung
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality; D005260:Female; D006801:Humans; D015994:Incidence; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009389:Neovascularization, Pathologic / Q000453:epidemiology; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin
references.citation: Lung Cancer. 2013 Feb;79(2):180-6
references.pmid: 23218791
references.citation: J Thorac Oncol. 2011 Aug;6(8):1359-66
references.pmid: 21587085
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):3974-86
references.pmid: 15930332
references.citation: Biol Proced Online. 2004;6:250-256
references.pmid: 15514699
references.citation: Am J Clin Pathol. 2003 Nov;120(5):712-9
references.pmid: 14608897
references.citation: Clin Cancer Res. 2012 May 1;18(9):2443-51
references.pmid: 22407829
references.citation: Lancet. 2011 Nov 12;378(9804):1727-40
references.pmid: 21565398
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5198-203
references.pmid: 18824702
references.citation: Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98
references.pmid: 11483992
references.citation: J Pathol. 2003 Aug;200(5):620-6
references.pmid: 12898598
references.citation: J Thorac Oncol. 2012 Feb;7(2):323-30
references.pmid: 22237264
references.citation: N Engl J Med. 2008 Sep 25;359(13):1367-80
references.pmid: 18815398
references.citation: Nat Med. 1997 Aug;3(8):917-21
references.pmid: 9256286
references.citation: Neoplasia. 2002 Mar-Apr;4(2):141-50
references.pmid: 11896569
references.citation: J Clin Pathol. 2006 Aug;59(8):790-800
references.pmid: 16873561
references.citation: Ann Oncol. 2004 Nov;15(11):1654-60
references.pmid: 15520067
references.citation: Cancer Res. 2010 Dec 15;70(24):10402-10
references.pmid: 21159653
references.citation: Mol Biol Rep. 2013 Feb;40(2):917-24
references.pmid: 23065255
references.citation: PLoS One. 2012;7(2):e31906
references.pmid: 22363766
references.citation: Br J Cancer. 2007 Feb 26;96(4):639-45
references.pmid: 17285125
references.citation: Lung Cancer. 2008 Jul;61(1):91-6
references.pmid: 18192073
references.citation: Cancer Treat Rev. 2013 Nov;39(7):802-11
references.pmid: 23453862
references.citation: Cancer Lett. 2006 Dec 8;244(2):164-71
references.pmid: 16621243
references.citation: J Cell Biochem. 2003 Apr 1;88(5):885-98
references.pmid: 12616528
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: PLoS One. 2012;7(3):e34100
references.pmid: 22457815
references.citation: Clin Cancer Res. 2011 Apr 15;17(8):2140-8
references.pmid: 21415216
references.citation: Respir Med. 2006 Dec;100(12):2220-6
references.pmid: 16650973
references.citation: Virchows Arch. 2006 Aug;449(2):164-70
references.pmid: 16810543